ERBB2 and breast carcinoma: Nowadays, few predictive markers were found for HER2+ BC patients with trastuzumab resistance, and our study was the first research to reveal that circCDYL2 and GRB7 were essential genes in regulating trastuzumab sensitivity of HER2+ breast cancer.